Biote (BTMD) Stock: Buy, Sell, or Hold?
BTMD - Biote Corp. Class A Common Stock
$1.07
-0.03 (-2.29%)
▼
5d:
-1.84%
30d:
-13.41%
90d:
-54.29%
BUY
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 04, 2026
11d
Get Alerted When BTMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BTMD shows positive signals but monitor for confirmation. Market pricing in 8.8% decline. Moderate conviction.
💡 BUY OPPORTUNITY: BTMD shows positive signals but monitor for confirmation. Market pricing in 8.8% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.80
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$1.74
38.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 3.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BTMD is currently trading at $1.06, which is considered oversold relative to its 30-day fair value range of $1.08 to $1.30. From a valuation perspective, the stock is trading at a discount (Forward PE: 2.4) compared to its historical average (3.2). Remarkably, the market is currently pricing in an annual earnings decline of 8.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BTMD is in a strong downtrend. Immediate support is located at $1.00, while resistance sits at $1.25.
Market Sentiment: BTMD scores 67/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $2.61 (+139.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BTMD is in a strong downtrend. Immediate support is located at $1.00, while resistance sits at $1.25.
Market Sentiment: BTMD scores 67/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $2.61 (+139.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.08 -
$1.30
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (67/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 139.6% below Wall St target ($2.61)
- BULLISH: Bottoming setup score 67/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$1.08 -
$1.30
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.00
Resistance Level
$1.25
Current Trend
Strong Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
2.42
Wall Street Target
$2.61
(+139.6%)
Revenue Growth (YoY)
-9.5%
Earnings Growth (YoY)
-83.8%
Profit Margin
3.2%
Valuation Discount vs History
-8.8% cheaper
PE vs Historical
2.4 vs 3.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.8%
(market-implied from PE analysis)
1-Year Target
$0.99
(-9%)
2-Year Target
$0.91
(-17%)
3-Year Target
$0.83
(-24%)
3-Yr Target (if PE normalizes)
(PE: 2→3)
$1.09
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 28.6%)
$18.99
(+1643%)
Base:
(SPY PE: 2.4, Growth: 28.6%)
$2.32
(+113%)
Bear:
(PE: 2.1, Growth: 28.6%)
$1.97
(+81%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (7x PE), but valuation improves significantly next year (2x PE) as earnings recover.
Trailing PE: 7.36 | Current EPS (TTM): $0.14
Bull Case
$2.27
(+108%)
Analyst growth 100.0%, PE expands to 8.1
Base Case
$2.06
(+89%)
Market implied 100.0%, PE stable at 7.4
Bear Case
$0.70
(-36%)
Severe decline -20.0%, PE contracts to 6.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 2.4 to 3.2
Stabilization Target:
$1.44
(+32.1%)
PE Expansion Potential:
+32.1%
Share & Embed Analysis
Last updated: October 23, 2026 1:05 PM ET
Data refreshes hourly during market hours. Next update: 2:05 PM
Data refreshes hourly during market hours. Next update: 2:05 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BTMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Care Facilities Stocks
Top-rated stocks in Medical Care Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
THC
Tenet Healthcare Corpora… |
STRONG BUY
23 analysts |
$286 | 51 HOLD |
|
HCA
HCA Healthcare, Inc. |
BUY
26 analysts |
$461 | 49 HOLD |
|
EHC
Encompass Health Corp |
STRONG BUY
13 analysts |
$148 | 61 BUY |
|
CMPS
Compass Pathways Plc |
STRONG BUY
16 analysts |
$24 | 50 HOLD |
|
ADUS
Addus HomeCare Corporati… |
STRONG BUY
14 analysts |
$134 | 54 HOLD |
